NIH paused clinical trials for stroke drug 3K3A-APC, co-founded by USC neuroscientist Zlokovic, due to data problems in his research papers leading to retractions and corrections.
High-tier influential papers by Zlokovic facing retractions, corrections, and expressions of concern highlight the significance of the integrity issues in his research work.
Whistleblower report led by Dr. Matthew Schrag independently of Vanderbilt raised alarms on Zlokovic's research, prompting USC to undertake an ongoing review.
USC and Zlokovic representatives refrain from commenting, emphasizing the seriousness of ongoing allegations regarding research integrity reported in the journal Science.
Collection
[
|
...
]